The 8th American college of chest physicians guidelines - A perspective on venous thromboembolism guidelines

Thrombosis and Haemostasis

Volumn 101, Issue 1, 2009, Pages 31-35

  Squizzato, Alessandro ^a   Ageno, Walter ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; LUNG EMBOLISM; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; AMBULATORY CARE; ARTHROSCOPY; DRUG ADMINISTRATION; EUROPE; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; KNEE; MEDICAL SOCIETY; NEOPLASM; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AMBULATORY CARE; ANTICOAGULANTS; ARTHROSCOPY; DRUG ADMINISTRATION SCHEDULE; EUROPE; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; KNEE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PULMONARY EMBOLISM; RISK FACTORS; SOCIETIES, MEDICAL; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 60849084893     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-08-0519     Document Type: Article

References (32)

1. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 454S-545S.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S.
3. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 401S-428S.
4. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfraclionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. J Am Med Assoc 2006; 296: 935-942.
5. Meyer G, et al. PEITHO Pulmonary Embolism Thrombolysis Study, http://clinicaltrials.gov/ct2/show/NCT00639743?term=pulmonary+embolism&rank= 13.
6. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
7. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-687.
8. Ageno W, Steidl L, Marchesi C, et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica 2002; 87: 286-291.
9. Agnelli G. Verso M, Ageno W, et al. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008; 121: 605-610.
10. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809-1812.
11. Wicki J, Perrier A, PernegerTV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 548-552.
12. Aujesky D, Obrosky DS, Stone RA, et al. A prediction rule to identify low-risk patients with pulmonary-embolism. Arch Intern Med 2006; 166: 169-175.
13. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I-4-I-8.
14. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
15. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. J Am Med Assoc 2003; 290: 1071- 1074.
16. Siragusa S, Malato A, Anastasio R. et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study. Blood 2008; 112: 511-515.
17. Prandoni P. Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-960.
18. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434.
19. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
20. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
21. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325-329.
22. Hull RD, Schellong SM, Tapson VF, et al. Extended duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study [abstract]. J Thromb Haemost 2007; 5 (Suppl 2): O-S-001.
23. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.
24. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-930.
25. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis: a meta-analysis. Thromb Haemost 2007; 97: 1031-1036.
26. Palumbo A, Rus C, Zeldis JB, et al. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4: 1842-1845.
27. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
28. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. J Am Med Assoc 2006; 296: 2558-2560.
29. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
30. Ramos J, Perrotta C, Badariotti G, et al. Interventions for preventing venous thromboembolism in adults undergoing knee athroscopy. Cochrane Database Syst Rev 2007; issue 2: article No. CD005259.
31. Camporese G, Bernardi E, Prandoni P, et al. Lowmolecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 2008; 149: 73-82.
32. Ageno W, Dentali F, Imberti D. A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery. J Thromb Haemost 2004; 2: 1901-1902.